Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation - Kamel, S; Horton, L; Ysebaert, L; Levade, M; Burbury, K; Tan, S; Cole-Sinclair, M; Reynolds, J; Filshie, R; Schischka, S; Khot, A; Sandhu, S; et al. (Leukemia, 2015)
Keywords: 631/443/1338/1339; 631/67/1059/602; 631/67/1990/283/1895; 692/699/1541; 692/700/565/1436; Adenine - analogs & derivatives; Adenosine; Adenosine diphosphate; Adenosine Diphosphate - pharmacology; Aged; Aged, 80 and over; Agglomeration; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; ATPases; Bleeding; Blood Platelets - drug effects; Blood Platelets - pathology; Bruising; Bruton's tyrosine kinase; Cancer Research; Cells, Cultured; Chronic lymphocytic leukemia; Collagen; Collagen - pharmacology; Critical Care Medicine; Defects; Drug therapy; Enzyme inhibitors; Female; Gaging; Genetic aspects; Glycoprotein VI; Glycoproteins; Health aspects; Hematology; Hemorrhage - chemically induced; Hemorrhage - diagnosis; Hemorrhage - pathology; Humans; Ibrutinib; Inhibitor drugs; Intensive; Internal Medicine; Kinases; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - pathology; Light transmission; Lymphoma, Mantle-Cell - drug therapy; Lymphoma, Mantle-Cell - pathology; Male; Medicine; Medicine & Public Health; Middle Aged; Oncology; original-article; Patients; Physiological aspects; Piperidines; Platelet aggregation; Platelet Aggregation - drug effects; Protein-tyrosine kinase; Pyrazoles - administration & dosage; Pyrazoles - adverse effects; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Receiving; Severity of Illness Index; Tyrosine; Australia